Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.80 |
| ▸ | MMP9 | P14780 | 3/20 | 0.80 |
| ▸ | MMP8 | P22894 | 3/20 | 0.80 |
| ▸ | MMP13 | P45452 | 3/20 | 0.80 |
| ▸ | COMT | P21964 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.77 |
| ▸ | MEN1 | O00255 | 6/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | POLB | P06746 | 4/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | ATM | Q13315 | 1/20 | 0.77 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147901 | 0.94 | MMP2 (0.75) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL16147815 | 0.91 | KMT2A (0.69) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL2250333 | 0.89 | COMT (1.00) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL22839407 | 0.87 | MMP2 (0.62) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL31578829 | 0.87 | MAPT (1.00) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL2582594 | 0.87 | MAPT (1.00) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL27202547 | 0.87 | MMP2 (0.76) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL27202472 | 0.87 | MMP2 (0.76) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL31472953 | 0.87 | KDM4E (0.73) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL28591279 | 0.87 | KDM4E (0.73) | MMP2MMP9MMP8MMP13COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3757099-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11197891-B2 | Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith | LANDOS BIOPHARMA, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210046070-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| EP-3757099-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10849895-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200261447-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3209655-B1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20180055841-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-20180055841-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANDOS BIOPHARMA, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| US-9839635-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839635-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANDOS BIOPHARMA, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9556146-B2 | Lanthionine synthetase C-like 2-based therapeutics | BIOTHERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556146-B2 | Lanthionine synthetase C-like 2-based therapeutics | BIOTHERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | BIOTHERAPEUTICS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046070-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-20180055841-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-20160115153-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-20200261447-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-11571419-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-11197891-B2 | Therapies with lanthionine C-like protein 2 ligands and cells prepared therewith | LCP2, LANCL2, CALCB | MMP2 4860/4885MMP9 4854/4885MMP8 4385/4885 |
| US-20230142910-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-10849895-B2 | Lanthionine synthetase C-like 2-based therapeutics | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
| US-20170119762-A1 | LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS | LANCL2, CBS, LCP2 | MMP2 4031/4885MMP9 3780/4885MMP8 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.